TY - JOUR T1 - In vitro susceptibility of mycobacterium bovis against moxifloxacin JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p4417 AU - Timo Weiss AU - Torsten Blum AU - Jens Kollmeier AU - Harald Mauch AU - Holger Russmann AU - Nicolas Schönfeld AU - Torsten T. Bauer Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p4417.abstract N2 - Introduction: Mycobacterium bovis, the causative agent of bovine tuberculosis is also responsible for diseases in humans. To date there are no data available on the in vitro susceptibility of M. bovis strains to moxifloxacin, an established second line drug in the treatment of disease caused by M. tuberculosis.Methods: From M. bovis-positive cultures from BAL, sputum, pleural effusion or cerebrospinal fluid of 34 pts from the years 1993-2010, we retrospectively evaluated the sensitivity in vitro and the minimum inhibitory concentrations of moxifloxacin. Culturing and resistance testing was performed on solid Middlebrook agar plates.Results: Out of 34 tested M. bovis-positive cultures 33 showed a sensitivity to moxifloxacin at 2 or 4 mcg/ml. Only one strain showed resistance.Conclusion: Our study of a small group of patients shows a high sensitivity rate of moxifloxacin against M. bovis strains. Despite the absence of clinical treatment studies, we see a potential use of moxifloxacin as a second line drug, with regular ineffectiveness of the first-line drug pyrazinamide in M. bovis. ER -